AIML Subsidiary NeuralCloud Solutions and Toronto Heart Centre Launch a Pilot Program to Test AI-Powered Holter ECG Reporting
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) announced that its subsidiary NeuralCloud Solutions is launching a pilot with the Toronto Heart Centre to evaluate CardioYield™, the company's AI visualization and reporting interface powered by MaxYield™. The study will compare Holter ECG reporting workflows, measuring technician efficiency, report turnaround time, and analysis quality versus current industry-standard software.
The release describes CardioYield™ features including automated removal of baseline wander and motion artifacts, beat-level PQRST labeling with interval calculations, and a unified reporting interface intended to reduce repetitive corrections and analyst fatigue. Management and clinical leaders framed the pilot as a step to quantify efficiency and diagnostic reliability in real-world practice.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) ha annunciato che la sua controllata NeuralCloud Solutions sta avviando un pilota presso il Toronto Heart Centre per valutare CardioYield™, l'interfaccia di visualizzazione e reporting basata sull'IA dell'azienda alimentata da MaxYield™. Lo studio confronterà i flussi di lavoro di reporting Holter ECG, misurando efficienza del tecnico, tempo di turnaround dei report e qualità dell'analisi rispetto al software standard di settore attuale.
Il comunicato descrive le caratteristiche di CardioYield™ tra cui rimozione automatica delle variazioni di baseline e degli artefatti da movimento, etichettatura PQRST a livello di battito con calcoli di intervallo, e un'interfaccia di reporting unificata finalizzata a ridurre correzioni ripetitive e affaticamento degli analisti. La direzione e i leader clinici hanno inquadrato il pilota come un passo per quantificare efficienza e affidabilità diagnostica in pratica reale.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) anunció que su filial NeuralCloud Solutions está lanzando un piloto con el Toronto Heart Centre para evaluar CardioYield™, la interfaz de visualización e informes impulsada por IA de la empresa, potenciada por MaxYield™. El estudio comparará los flujos de trabajo de informes Holter ECG, midiendo la eficiencia del técnico, el tiempo de entrega de los informes y la calidad del análisis frente al software estándar de la industria actual.
El comunicado describe las características de CardioYield™ incluyendo la eliminación automatizada de la deriva de la línea de base y de los artefactos de movimiento, el etiquetado a nivel de latido PQRST con cálculos de intervalos, y una interfaz unificada de informes destinada a reducir correcciones repetitivas y la fatiga de los analistas. La dirección y los líderes clínicos enmarcaron el piloto como un paso para cuantificar la eficiencia y la fiabilidad diagnóstica en la práctica real.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF)는 자회사 NeuralCloud Solutions가 토론토 하트 센터와 함께 파일럿을 시작해 CardioYield™를 평가한다고 발표했습니다. 이 회사의 AI 시각화 및 보고 인터페이스는 MaxYield™로 구동됩니다. 연구는 Holter ECG 보고 워크플로를 비교하고 기술자 효율성, 보고서 처리 시간, 및 분석 품질을 현재 업계 표준 소프트웨어와 대조합니다.
발표는 Baseline wander 및 움직임 아티팩트의 자동 제거, 비트 수준 PQRST 표기와 구간 계산, 그리고 반복 수정과 애널리스트 피로를 줄이려는 통합 보고 인터페이스를 포함한 CardioYield™의 기능을 설명합니다. 경영진과 임상 리더는 파일럿을 실제 현장에서의 효율성과 진단 신뢰도를 정량화하는 단계로 설명했습니다.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) a annoncé que sa filiale NeuralCloud Solutions lance un pilote avec le Toronto Heart Centre pour évaluer CardioYield™, l'interface de visualisation et de reporting alimentée par l'IA de l'entreprise, propulsée par MaxYield™. L'étude comparera les flux de travail de reporting Holter ECG, mesurant l'efficacité du technicien, le délai de restitution des rapports et la qualité de l'analyse par rapport au logiciel standard actuel de l'industrie.
Le communiqué décrit les fonctionnalités de CardioYield™ comprenant la suppression automatisée des dérives de la ligne de base et des artefacts de mouvement, le marquage PQRST au niveau du battement avec des calculs d'intervalles, et une interface de reporting unifiée destinée à réduire les corrections répétitives et la fatigue des analystes. La direction et les responsables cliniques ont encadré le pilote comme une étape pour quantifier l'efficacité et la fiabilité diagnostique en pratique réelle.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) gab bekannt, dass seine Tochtergesellschaft NeuralCloud Solutions ein Pilotprojekt mit dem Toronto Heart Centre startet, um CardioYield™, die KI-Visualisierungs- und Reporting-Schnittstelle des Unternehmens, unterstützt durch MaxYield™, zu evaluieren. Die Studie wird Holter-EKG-Berichts-Workflows vergleichen und Techniker-Effizienz, Bericht-Umsetzungszeit und Analysequalität gegenüber der aktuellen Branchen-Standardsoftware messen.
Die Mitteilung beschreibt CardioYield™-Funktionen, darunter automatisierte Entfernung von Baseline-Wanderungen und Bewegungsartefakten, bitgenaues PQRST-Labeling mit Intervallberechnungen und eine einheitliche Reporting-Schnittstelle, die darauf abzielt, wiederholte Korrekturen und Analysten-Fatigue zu reduzieren. Geschäftsführung und klinische Leiter sahen im Pilot einen Schritt zur Quantifizierung von Effizienz und diagnostischer Zuverlässigkeit in der Praxis.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) أعلنت أن شركتها الفرعية NeuralCloud Solutions ستطلق برنامجاً تجريبياً مع Toronto Heart Centre لتقييم CardioYield™، واجهة التصور والتقارير المدعومة بالذكاء الاصطناعي من الشركة، المشغّلة بواسطة MaxYield™. ستقارن الدراسة تدفقات عمل تقارير Holter ECG، مع قياس كفاءة الفني، زمن تسليم التقارير، وجودة التحليل مقارنةً ببرنامج القياس القياسي الصناعي الحالي.
يصف الإصدار ميزات CardioYield™ بما في ذلك إزالة تلقائية لانحراف الأساس والأ artefacts الحركة، التوسيم PQRST عند مستوى النبضة مع حسابات الفواصل، وواجهة تقارير موحدة تهدف إلى تقليل التصحيحات المتكررة وإرهاق المحللين. وصفت الإدارة والقادة السرّيونPilot كخطوة لتحديد الكفاءة واعتمادية التشخيص في الممارسة الواقعية.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) 宣布其子公司 NeuralCloud Solutions 正在与 多伦多心脏中心 联合启动试点，以评估 CardioYield™，该公司的 AI 可视化与报告界面，由 MaxYield™ 提供动力。该研究将比较 Holter ECG 报告工作流程，衡量 技师效率、报告周转时间，以及 分析质量，与当前行业标准软件相比。
新闻稿描述 CardioYield™ 的功能，包括自动去除基线漂移和运动伪影、逐拍的 PQRST 标记及区间计算，以及旨在减少重复更正和分析师疲劳的统一报告界面。管理层和临床领导人将该试点视为在真实世界实践中量化效率和诊断可靠性的一步。
- None.
- None.
Pilot Evaluation: Toronto Heart Centre to conduct comparative testing of CardioYield™ for enhanced Holter ECG analysis and reporting efficiency.
Clinical Workflow Impact: Study to measure time savings, throughput improvements, and analysis quality when using CardioYield™ versus current industry-standard software.
TORONTO, ON, AB / ACCESS Newswire / October 7, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc., is entering a collaborative pilot study evaluating CardioYield™ with the Toronto Heart Centre.
CardioYield™ is Neural Cloud's visualization and reporting interface that is powered by MaxYield™, the Company's AI-powered ECG signal-processing platform.
The Toronto Heart Center brings together over 20 leading cardiologists from St. Michael's Hospital to provide comprehensive cardiovascular care. Offering everything from consultations to advanced diagnostics and specialized clinics, it delivers a one-stop access to heart health services in the community.
The pilot study will directly compare Holter ECG reporting workflows at the Toronto Heart Center, assessing technician efficiency, report turnaround time, and analysis quality.
The Role of CardioYield™ in Holter ECG Reporting:
Time and throughput gains: Designed to reduce report completion time and potentially increase technician throughput.
Neuralized signal clarity: Automated removal of baseline wander, motion artifacts, and muscle noise.
Beat-level precision: Automated PQRST labeling with interval calculations for QT, PR, RR, and ST segments.
Streamlined reporting: Unified interface potentially reducing repetitive corrections and analyst fatigue.
Management Commentary
Dr. Chi Ming Chow - Cardiologist, St. Michael's Hospital / President, Heart and Stroke Foundation of Ontario / Toronto Heart Centre
"We are pleased to collaborate with AIML and Neural Cloud on this pilot study. Holter reporting remains a time-intensive process, and innovations like CardioYield™ offer the potential to improve both speed and diagnostic reliability, benefiting clinicians and patients alike."
Esmat Naikyar - Chief Product Officer, AIML / President, Neural Cloud Solutions
"CardioYield™ was designed side-by-side with ECG technicians and cardiologists, and this study is an opportunity to demonstrate measurable value in real-world clinical practice. Partnering with the Toronto Heart Centre allows us to directly quantify efficiency gains that could reshape how Holter data is processed and reported."
Paul Duffy - CEO, AIML
"This pilot with the Toronto Heart Centre represents an important milestone: applying our AI-driven analytics directly in a clinical workflow. CardioYield™ has the potential to meaningfully improve efficiency and accuracy in Holter reporting, and we're eager to validate that impact in collaboration with one of Canada's most respected cardiology centres."
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
Contact:
Blake Fallis
(778) 405-0882
info@aiml.health
About AIML Innovations Inc.
https://www.aiml.health/
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire
FAQ
What is AIML announcing on October 7, 2025 regarding CardioYield™ (AIMLF)?
What will the Toronto Heart Centre pilot measure for AIML's CardioYield™ (AIMLF)?
How does CardioYield™ aim to improve Holter ECG reporting for AIML (AIMLF)?
Who is partnering with AIML on the CardioYield™ pilot study?
Will the pilot with Toronto Heart Centre provide clinical validation for AIML's CardioYield™ (AIMLF)?
Where can investors find more information about AIML and the CardioYield™ pilot?
